J Schupbach

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. ncbi request reprint Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Int Arch Allergy Immunol 132:196-209. 2003
  2. ncbi request reprint HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
  3. ncbi request reprint HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 33:292-9. 2003
  4. ncbi request reprint Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Gloriastr 30, CH 8028 Zurich Switzerland
    AIDS Rev 4:83-92. 2002
  5. ncbi request reprint Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA
    J Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 65:225-32. 2001
  6. ncbi request reprint Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure
    J Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Gloriastrasse 30, CH 8028 Zurich, Switzerland
    Int J Antimicrob Agents 16:441-5. 2000
  7. ncbi request reprint Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 78:1003-10. 2006
  8. doi request reprint Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    HIV Med 12:279-88. 2011
  9. doi request reprint Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 57:24-31. 2011
  10. pmc Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 203:791-7. 2011

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Int Arch Allergy Immunol 132:196-209. 2003
    ..p24 antigen is an excellent marker of HIV expression and disease activity and can be used in the same fields of application as HIV RNA is used. The test is validated for subtype B, but requires further studies for non-B subtypes...
  2. ncbi request reprint HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
    ..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
  3. ncbi request reprint HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 33:292-9. 2003
    ..Comparison of p24 antigen and HIV-1 RNA concentrations indicate that the p24 antigen detected in these samples is not associated with viral RNA-containing particles and may originate from other compartments of virus expression...
  4. ncbi request reprint Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Gloriastr 30, CH 8028 Zurich Switzerland
    AIDS Rev 4:83-92. 2002
    ..There is no problem with sample instability and no need for cumbersome nucleic acid extraction. The test is validated for subtype B, but requires further studies for non-B subtypes...
  5. ncbi request reprint Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA
    J Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 65:225-32. 2001
    ..5% of those for RNA (P <.0001). These results indicate that heat-denatured, amplification-boosted p24 antigen measurement can be used as a simple and inexpensive alternative to HIV RNA testing for monitoring treatment...
  6. ncbi request reprint Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure
    J Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Gloriastrasse 30, CH 8028 Zurich, Switzerland
    Int J Antimicrob Agents 16:441-5. 2000
    ..The lower costs of p24 testing also permit a closer monitoring of patients with an earlier detection of anti-retroviral treatment failures...
  7. ncbi request reprint Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 78:1003-10. 2006
    ..It also uncovers the presence of a p24 reactivity, whose identity remains to be determined, in a significant fraction of samples with undetectable HIV-1 RNA under long-term HAART...
  8. doi request reprint Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    HIV Med 12:279-88. 2011
    ..The long-term outcome of antiretroviral therapy (ART) is not assessed in controlled trials. We aimed to analyse trends in the population effectiveness of ART in the Swiss HIV Cohort Study over the last decade...
  9. doi request reprint Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 57:24-31. 2011
    ..Nucleoside reverse transcriptase inhibitors (NRTIs) are often administered in salvage therapy even if genotypic resistance tests (GRTs) indicate high-level resistance, but little is known about the benefit of these additional NRTIs...
  10. pmc Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 203:791-7. 2011
    ..Following detection, individuals with Q151M tended to have lower suppression rates and higher mortality rates, relative to control subjects. Additional studies are needed to verify these findings in non-subtype B infections...
  11. pmc Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
    Marie Ballif
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 4:e8275. 2009
    ..Combination antiretroviral treatment (cART) has been very successful, especially among selected patients in clinical trials. The aim of this study was to describe outcomes of cART on the population level in a large national cohort...
  12. doi request reprint Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors
    Annette Audigé
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
    AIDS Res Hum Retroviruses 26:997-1005. 2010
    ..The lack of an effect of ART on CD4 density implies a persistent dysfunctional immune response by uncontrolled HIV infection...
  13. doi request reprint Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study
    Barbara Hasse
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
    Clin Infect Dis 51:1314-22. 2010
    ..We studied the frequency, changes over time, and determinants of unprotected sex among HIV-positive persons...
  14. doi request reprint Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 53:464-71. 2010
    ..Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited...
  15. doi request reprint Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study
    R Weber
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Raemistrasse 100, Zurich CH 8091, Switzerland
    HIV Med 10:407-16. 2009
    ..Design A prospective observational study of all participants in the Swiss HIV Cohort Study followed between 1997 and 2006 was carried out...
  16. doi request reprint HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Clin Infect Dis 51:620-8. 2010
    ..We investigated this matter by analyzing genotypic resistance tests covering 400 amino acid positions in the RT of HIV-1 subtype B viruses and corresponding treatment histories and laboratory measurements...
  17. ncbi request reprint B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-α response to TLR9 triggering
    Annette Audigé
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
    AIDS Res Hum Retroviruses 26:1063-74. 2010
    ..Finally, since increased IL-6 expression is linked to EBV-associated Hodgkin’s lymphoma, the enhanced baseline expression of IL-6 might be important in the pathogenesis of PCNSL in HIV-infected patients...
  18. pmc High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease
    Jorg Schupbach
    University of Zurich, Institute of Medical Virology, Swiss National Center for Retroviruses, Zurich, Switzerland
    BMC Infect Dis 11:254. 2011
    ..Here, we sought to further investigate the diagnostic specificity of various Inno-Lia algorithms and to identify factors affecting it...
  19. ncbi request reprint Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection
    D Nadal
    Pediatric Infectious Diseases Unit, Universitäts Kinderklinik, CH 8032 Zurich, Switzerland
    J Infect Dis 180:1089-95. 1999
    ..002). Variation of RNA concentrations was more marked than that of p24 antigen (P=.002). The p24 antigen test was equivalent to PCR for diagnosing and monitoring pediatric HIV-1 infection...
  20. pmc Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA
    R N Weissmahr
    Swiss National Center for Retroviruses, University of Zurich
    J Virol 71:3005-12. 1997
    ..Furthermore, complexes of naturally primed EAV-0(B1) RNA with RT were demonstrated. Taken together, these data strongly suggest that EAV-0 is able to produce virus-like particles with an active RT...
  21. doi request reprint High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients
    Nicolas J Mueller
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital of Zurich, Zurich, Switzerland
    AIDS 24:1127-34. 2010
    ..To evaluate the prevalence of 25-hydroxyvitamin D [25(OH)D] deficiency in HIV-positive patients, a population at risk for osteoporosis...
  22. doi request reprint Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection
    Anna Haas
    Institute of Microbiology, ETH Zurich, Zurich, Switzerland
    Gut 60:1506-19. 2011
    ..The mechanisms underlying B cell hyperactivation and the specificities of the resulting hypergammaglobulinaemia are only poorly understood...
  23. ncbi request reprint Detection of high concentrations of HTLV-1 p24 and a novel gag precursor, p45, in serum immune complexes of a healthy seropositive individual
    J Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Switzerland
    Int J Cancer 44:90-4. 1989
    ..The results present direct evidence of production of HTLV-1 proteins in an asymptomatically infected individual...
  24. ncbi request reprint Immunophilins and HIV-1 infection
    D Minder
    Institute of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Arch Virol 147:1531-42. 2002
    ..We therefore may conclude that endogenous CypA exerts its action after reverse transcription but before virus maturation, probably during capsid formation. FK520, an immunosuppressor which binds to FKBP, had no effect on HIV-1 infection...